| Phase 15 trials |
|
Phase 1
|
NCT07115446 |
Aug 2025 → Dec 2027 expected |
prostate cancer |
Hansoh BioMedical R&D Company |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07014488 |
Jun → Aug 2025 |
prostate cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06830850 |
Jun 2025 → Dec 2026 expected |
castration-resistant prostate carcinoma |
Atridia Pty Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06559007 |
Sep 2024 → Jan 2025 |
prostate cancer |
Atridia Pty Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05942001 |
Aug 2023 → Aug 2025 overdue |
prostate cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT06568094 |
Sep 2024 → Jun 2026 overdue |
prostate cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT06738745 |
Dec 2024 → Jan 2027 expected |
metastatic prostate carcinoma |
Fudan University |
Not yet recruiting
|
No outcome recorded
|